Pilot Study of mTOR Inhibitor Therapy in Peutz-Jeghers Syndrome
NCT00811590 is a phase 2 interventional trial sponsored by University of Utah. As of 21 Nov 2026, it was terminated. It studies Everolimus in Peutz-Jeghers Syndrome. The registry lists an enrollment of 3 participants at 1 site in 1 country. The registry lists a start date of 30 Nov 2008 and a primary completion date of 31 Mar 2011.
Key facts
Registry attributes as recorded on the ClinicalTrials.gov study record.
| Field | Value |
|---|---|
| Registry ID | NCT00811590 |
| Status | Terminated |
| Phase | Phase 2 |
| Study type | Interventional trial |
| Lead sponsor | University of Utah |
| Enrollment | 3 |
| Registered sites | 1 |
| Countries | 1 |
| Conditions | Peutz-Jeghers Syndrome |
| Drugs | Everolimus |
| Start | 30 Nov 2008 |
| Primary completion | 31 Mar 2011 |
| Study completion | 31 Mar 2011 |
| Last update posted | 19 Sept 2024 |
Registered summary
The lay summary the sponsor registered on ClinicalTrials.gov.
Investigators
The overall officials registered on this study. Names that resolve to a FindMyKOL profile link to it; the rest are shown as registered.
- Randall W Burt, MD
Huntsman Cancer Institute
Principal Investigator - Scott Kuwada, MD
University of Hawaii
Study Chair
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
1 registered facility, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Huntsman Cancer Institute
Salt Lake City
United States, by state
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.
Questions about NCT00811590
Each answer restates registry values shown on this page.
What is NCT00811590?
NCT00811590 is a phase 2 interventional trial sponsored by University of Utah. It studies Everolimus in Peutz-Jeghers Syndrome.
Who leads NCT00811590?
The registry names Randall W Burt, MD (principal investigator, Huntsman Cancer Institute) and Scott Kuwada, MD (study chair, University of Hawaii) as overall officials.
Where does NCT00811590 run?
The registry lists 1 site in 1 country. Every site with a stated country is in one country: United States.
Which drugs does NCT00811590 study?
The registered drug and biological interventions are Everolimus.
When did NCT00811590 end?
The registry lists a primary completion date of 31 Mar 2011 and a study completion date of 31 Mar 2011. The sponsor last updated the record on 19 Sept 2024.
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 21 Nov 2026. Registry facts are shown as registered by the study sponsor; FindMyKOL does not interpret them.